Mode
Text Size
Log in / Sign up
Phase 4 Completed N=72 Randomized Quadruple-blind Treatment

LIPT - Liraglutide in Polycystic Ovary Syndrome

Source: ClinicalTrials.gov NCT02073929 ↗
Enrolled (actual)
72
Serious AEs
4.2%
Results posted
Feb 2019
Primary outcomePrimary: Change in Endogenous Thrombin Potential (ETP) — -56.7; -8.2 nMolar x minutes
◆ Published Evidence
Highly cited
165citations · ~21 / year
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Diabetes, obesity & metabolism · 2018 · Likely link

Summary

Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.

Linked Publications

  • Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Diabetes, obesity & metabolism · 2018 · 165 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Endogenous Thrombin Potential (ETP)
-56.7; -8.2
SECONDARY
Percent Change in Plasma Level of Plasminogen Activator Inhibitor -1 PAI-1
-12; 4

Eligibility Criteria

Inclusion Criteria

  • PCOS
  • >18 years
  • premenopausal
  • BMI >25 og 25 and thereunder + insulin resistent

Exclusion Criteria (including):

  • actualt or intended pregnancy
  • inadeqvat contraception
  • hormonal contraception within 6 weeks
  • metfoomin, GLP-1-analog or DPP IV inhibitor within 3 months
  • medications affectiv hemostatic mechanisme
  • diabetes or other severe comorbidity
  • familar MEN
  • ...
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02073929) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search